MedElevator
Войти в исследования The journal of allergy and clinical immunology. Global · 2026
Circulating eosinophils in patients with hypereosinophilic syndrome have heterogeneous immunophenotypes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chhiba Krishan D, Kasjanski Richard, Makiya Michelle A, Brown Thomas, Khoury Paneez, Klion Amy D, Kuang Fei Li
Аннотация
BACKGROUND: Hypereosinophilic syndromes (HES) encompass a heterogeneous group of disorders characterized by blood and/or tissue hypereosinophilia. Despite recent advances, the diagnosis and management of HES remain challenging due to the lack of well-defined biomarkers of disease activity beyond blood eosinophilia.
OBJECTIVES: We sought to examine blood eosinophil immunophenotypes in patients with HES and determine whether typical markers of eosinophil activation and degranulation correlate with the presence of symptoms and/or treatment response in patients with HES.
METHODS: Peripheral blood samples were collected from 42 participants (39 patients with HES, 3 healthy donors). Clinical data were extracted by chart review. Surface expression of various eosinophil markers, including CD69, CD62L, CD66b, CD107a, CD107b, CD63, CCR3, CXCR4, CD101, and CD274, were quantified in whole blood by flow cytometry.
RESULTS: Absolute eosinophil counts were significantly elevated in symptomatic patients being treated for HES compared to asymptomatic patients being treated for HES. Cell surface expression of degranulation markers, CD107a and CD107b, and immunomodulatory protein CD274, were increased in patients being treated for HES. CCR3, a chemokine receptor for eotaxins, was increased on eosinophils from patients with myeloid HES on imatinib, but not on eosinophils from other patients with HES who are on treatment.
CONCLUSIONS: These findings enhance our understanding of the heterogeneity of circulating eosinophils in humans and may advance our ability to develop biomarkers of disease activity and effective therapy.
OBJECTIVES: We sought to examine blood eosinophil immunophenotypes in patients with HES and determine whether typical markers of eosinophil activation and degranulation correlate with the presence of symptoms and/or treatment response in patients with HES.
METHODS: Peripheral blood samples were collected from 42 participants (39 patients with HES, 3 healthy donors). Clinical data were extracted by chart review. Surface expression of various eosinophil markers, including CD69, CD62L, CD66b, CD107a, CD107b, CD63, CCR3, CXCR4, CD101, and CD274, were quantified in whole blood by flow cytometry.
RESULTS: Absolute eosinophil counts were significantly elevated in symptomatic patients being treated for HES compared to asymptomatic patients being treated for HES. Cell surface expression of degranulation markers, CD107a and CD107b, and immunomodulatory protein CD274, were increased in patients being treated for HES. CCR3, a chemokine receptor for eotaxins, was increased on eosinophils from patients with myeloid HES on imatinib, but not on eosinophils from other patients with HES who are on treatment.
CONCLUSIONS: These findings enhance our understanding of the heterogeneity of circulating eosinophils in humans and may advance our ability to develop biomarkers of disease activity and effective therapy.